Summary: Mediterranean Dietary Treatment in Hyperlipidemic Children: Should It Be an Option?

Summary: Effectiveness and safety of PCSK9 inhibitor therapy in patients with familial hypercholesterolemia within a therapeutic program in Poland: Preliminary multicenter data.

Summary: Hematological Inflammatory Markers in Patients with Clinically Confirmed Familial Hypercholesterolemia.

Summary: Features of chinese patients with sitosterolemia.

Summary: Relations of physical signs to genotype, lipid and inflammatory markers, coronary stenosis or calcification, and outcomes in patients with heterozygous familial hypercholesterolemia.

Summary: Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players.

Summary: Detection of Familial Hypercholesterolemia through centralized analytical data. HF HUELVA DETECTA Program.

Summary: Past, Present, and Future of Familial Hypercholesterolemia Management.

Summary: A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia.

Summary: Longitudinal evaluation of endothelial markers in children and adolescents with familial hypercholesterolemia.

Summary: Familial Hypercholesterolemia: JACC Focus Seminar 4/4.

Summary: Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors.